Premium
Langerhans cell histiocytosis (LCH): Guidelines for diagnosis, clinical work‐up, and treatment for patients till the age of 18 years
Author(s) -
Haupt Riccardo,
Minkov Milen,
Astigarraga Itziar,
Schäfer Eva,
Nanduri Vasanta,
Jubran Rima,
Egeler R. Maarten,
Janka Gritta,
Micic Dragan,
RodriguezGalindo Carlos,
Van Gool Stefaan,
Visser Johannes,
Weitzman Sheila,
Donadieu Jean
Publication year - 2013
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.24367
Subject(s) - medicine , langerhans cell histiocytosis , blood cancer , histiocytosis , childhood cancer , consensus conference , pediatrics , evidence based practice , intensive care medicine , cancer , family medicine , pathology , alternative medicine , disease
These guidelines for the management of patients up to 18 years with Langerhans cell histiocytosis (LCH) have been set up by a group of experts involved in the Euro Histio Net project who participated in national or international studies and in peer reviewed publications. Existing guidelines were reviewed and changed where new evidence was available in the literature up to 2012. Data and publications have been ranked according to evidence based medicine and when there was a lack of published data, consensus between experts was sought. Guidelines for diagnosis, initial clinical work‐up, and treatment and long‐term follow‐up of LCH patients are presented. Pediatr Blood Cancer 2013;60:175–184. © 2012 The Authors. Pediatric Blood & Cancer , published by Wiley Periodicals, Inc.